Literature DB >> 27334274

[The role of surgery for the management of resectable stage III non-small cell lung cancer].

Dirk Rades1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27334274     DOI： 10.1007/s00066-016-1001-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

Review 1.  Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer.

Authors:  S Y El-Sharouni; H B Kal; J J Battermann; F M N H Schramel
Journal:  Anticancer Res       Date:  2006 Jan-Feb       Impact factor: 2.480

2.  A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer.

Authors:  Weisan Zhang; Qian Liu; Xifeng Dong; Ping Lei
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

3.  Revisions in the International System for Staging Lung Cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

4.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

Authors:  Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

5.  10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).

Authors:  Wilfried Ernst Erich Eberhardt; Thomas Christoph Gauler; Cecile Lepechoux; Georgios Stamatis; Stephan Bildat; Thomas Krbek; Stefan Welter; Dominique Grunenwald; Berthold Fischer; Hepp de Los Rios Rodrigo; Dirk Theegarten; Thierry Le Chevalier; Siegfried Seeber; Martin Stuschke; Christoph Poettgen
Journal:  Lung Cancer       Date:  2013-08-16       Impact factor: 5.705

6.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors:  Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

7.  Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.

Authors:  Zuen Ren; Shijie Zhou; Zhidong Liu; Shaofa Xu
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

8.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

9.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Authors:  Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

10.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Authors:  Nasser Hanna; Marcus Neubauer; Constantin Yiannoutsos; Ronald McGarry; James Arseneau; Rafat Ansari; Craig Reynolds; Ramaswamy Govindan; Anton Melnyk; William Fisher; Donald Richards; Daniel Bruetman; Thomas Anderson; Naveed Chowhan; Sreenivasa Nattam; Prasad Mantravadi; Cynthia Johnson; Tim Breen; Angela White; Lawrence Einhorn
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.